GlipiZIDE Extended-Release Tablets — Class II drug recall D-0020-2022
Terminated recall by American Health Packaging, reported 2021-10-27, distributed nationwide. Failed Dissolution Specifications: results were above specification.
| Recall number | D-0020-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | American Health Packaging, Columbus, OH, United States |
| Recall initiated | 2021-09-17 |
| Classified | 2021-10-20 |
| Reported by FDA | 2021-10-27 |
| Terminated | 2023-06-08 |
| Distributed | Nationwide (US) |
| Quantity | 2,266 cartons |
| Reason classes | specification failure |
| NDC | 68084-0295-11, 68084-0295-21 |
| Lot numbers | 194141 |
| Expiration dates | 2022-03-31 |
Product
GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)
Reason for recall
Failed Dissolution Specifications: results were above specification.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0020-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.